Eintrag weiter verarbeiten
Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicent...
Gespeichert in:
| Zeitschriftentitel: | Japanese Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , |
| In: | Japanese Journal of Clinical Oncology, 2019 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Oxford University Press (OUP)
|
| Schlagwörter: |
| author_facet |
Yamazaki, Kentaro Matsumoto, Shigemi Imamura, Chiyo K Yamagiwa, Chiemi Shimizu, Ayaka Yoshino, Takayuki Yamazaki, Kentaro Matsumoto, Shigemi Imamura, Chiyo K Yamagiwa, Chiemi Shimizu, Ayaka Yoshino, Takayuki |
|---|---|
| author |
Yamazaki, Kentaro Matsumoto, Shigemi Imamura, Chiyo K Yamagiwa, Chiemi Shimizu, Ayaka Yoshino, Takayuki |
| spellingShingle |
Yamazaki, Kentaro Matsumoto, Shigemi Imamura, Chiyo K Yamagiwa, Chiemi Shimizu, Ayaka Yoshino, Takayuki Japanese Journal of Clinical Oncology Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study Cancer Research Radiology, Nuclear Medicine and imaging Oncology General Medicine |
| author_sort |
yamazaki, kentaro |
| spelling |
Yamazaki, Kentaro Matsumoto, Shigemi Imamura, Chiyo K Yamagiwa, Chiemi Shimizu, Ayaka Yoshino, Takayuki 1465-3621 Oxford University Press (OUP) Cancer Research Radiology, Nuclear Medicine and imaging Oncology General Medicine http://dx.doi.org/10.1093/jjco/hyz149 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Adjuvant capecitabine and oxaliplatin (CAPOX) is a standard treatment for resected colon cancer; however, in patients with moderate renal impairment, the incidence of CAPOX-related adverse events (AEs) and the rate of early discontinuation are higher than in patients with no or mild renal impairment. The aim of this retrospective study was to assess the impact of baseline renal function on the safety and discontinuation of adjuvant CAPOX therapy started with the standard dose of capecitabine in elderly patients with colon cancer.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Data from patients aged ≥65 years old who received CAPOX at the standard starting dose as adjuvant therapy for stage II/III colon cancer were collected and analyzed retrospectively. Patients were divided into two groups based on their renal function: CLcr-H (patients with a creatinine clearance [CLcr] ≥50 ml/min) and CLcr-L (CLcr <50 ml/min), and AEs and discontinuations were assessed.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Overall, 189 patients were assessed (CLcr-H group = 137 and CLcr-L group = 52). No patients experienced grade 4 AEs. The incidence of grade 3 CAPOX-related AEs was higher in the CLcr-L group (42.3%) than in the CLcr-H group (31.3%). The proportion of patients who discontinued treatment within four cycles due to AEs was also higher in the CLcr-L group (21.1%) than in the CLcr-H group (2.9%). Multivariate analysis identified that CLcr <50 ml/min was the only significant risk factor for CAPOX therapy discontinuation due to AEs (P = 0.0008).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>This study demonstrates that the tolerability of adjuvant CAPOX therapy was decreased in elderly patients with impaired renal function.</jats:p> </jats:sec> <jats:sec> <jats:title>Clinical trial registration</jats:title> <jats:p>University Hospital Medical Information Network Clinical Trials Registry number UMIN000016446.</jats:p> </jats:sec> Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study Japanese Journal of Clinical Oncology |
| doi_str_mv |
10.1093/jjco/hyz149 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9qamNvL2h5ejE0OQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9qamNvL2h5ejE0OQ |
| institution |
DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 |
| imprint |
Oxford University Press (OUP), 2019 |
| imprint_str_mv |
Oxford University Press (OUP), 2019 |
| issn |
1465-3621 |
| issn_str_mv |
1465-3621 |
| language |
English |
| mega_collection |
Oxford University Press (OUP) (CrossRef) |
| match_str |
yamazaki2019clinicalimpactofbaselinerenalfunctiononsafetyandearlydiscontinuationofadjuvantcapecitabineplusoxaliplatininelderlypatientswithresectedcoloncanceramulticenterpostmarketingsurveillancestudy |
| publishDateSort |
2019 |
| publisher |
Oxford University Press (OUP) |
| recordtype |
ai |
| record_format |
ai |
| series |
Japanese Journal of Clinical Oncology |
| source_id |
49 |
| title |
Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study |
| title_unstemmed |
Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study |
| title_full |
Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study |
| title_fullStr |
Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study |
| title_full_unstemmed |
Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study |
| title_short |
Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study |
| title_sort |
clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study |
| topic |
Cancer Research Radiology, Nuclear Medicine and imaging Oncology General Medicine |
| url |
http://dx.doi.org/10.1093/jjco/hyz149 |
| publishDate |
2019 |
| physical |
|
| description |
<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title>Background</jats:title>
<jats:p>Adjuvant capecitabine and oxaliplatin (CAPOX) is a standard treatment for resected colon cancer; however, in patients with moderate renal impairment, the incidence of CAPOX-related adverse events (AEs) and the rate of early discontinuation are higher than in patients with no or mild renal impairment. The aim of this retrospective study was to assess the impact of baseline renal function on the safety and discontinuation of adjuvant CAPOX therapy started with the standard dose of capecitabine in elderly patients with colon cancer.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods</jats:title>
<jats:p>Data from patients aged ≥65 years old who received CAPOX at the standard starting dose as adjuvant therapy for stage II/III colon cancer were collected and analyzed retrospectively. Patients were divided into two groups based on their renal function: CLcr-H (patients with a creatinine clearance [CLcr] ≥50 ml/min) and CLcr-L (CLcr <50 ml/min), and AEs and discontinuations were assessed.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results</jats:title>
<jats:p>Overall, 189 patients were assessed (CLcr-H group = 137 and CLcr-L group = 52). No patients experienced grade 4 AEs. The incidence of grade 3 CAPOX-related AEs was higher in the CLcr-L group (42.3%) than in the CLcr-H group (31.3%). The proportion of patients who discontinued treatment within four cycles due to AEs was also higher in the CLcr-L group (21.1%) than in the CLcr-H group (2.9%). Multivariate analysis identified that CLcr <50 ml/min was the only significant risk factor for CAPOX therapy discontinuation due to AEs (P = 0.0008).</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusions</jats:title>
<jats:p>This study demonstrates that the tolerability of adjuvant CAPOX therapy was decreased in elderly patients with impaired renal function.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Clinical trial registration</jats:title>
<jats:p>University Hospital Medical Information Network Clinical Trials Registry number UMIN000016446.</jats:p>
</jats:sec> |
| container_start_page |
0 |
| container_title |
Japanese Journal of Clinical Oncology |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792320731970797579 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T10:50:48.236Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Clinical+impact+of+baseline+renal+function+on+safety+and+early+discontinuation+of+adjuvant+capecitabine+plus+oxaliplatin+in+elderly+patients+with+resected+colon+cancer%3A+a+multicenter+post-marketing+surveillance+study&rft.date=2019-10-28&genre=article&issn=1465-3621&jtitle=Japanese+Journal+of+Clinical+Oncology&atitle=Clinical+impact+of+baseline+renal+function+on+safety+and+early+discontinuation+of+adjuvant+capecitabine+plus+oxaliplatin+in+elderly+patients+with+resected+colon+cancer%3A+a+multicenter+post-marketing+surveillance+study&aulast=Yoshino&aufirst=Takayuki&rft_id=info%3Adoi%2F10.1093%2Fjjco%2Fhyz149&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792320731970797579 |
| author | Yamazaki, Kentaro, Matsumoto, Shigemi, Imamura, Chiyo K, Yamagiwa, Chiemi, Shimizu, Ayaka, Yoshino, Takayuki |
| author_facet | Yamazaki, Kentaro, Matsumoto, Shigemi, Imamura, Chiyo K, Yamagiwa, Chiemi, Shimizu, Ayaka, Yoshino, Takayuki, Yamazaki, Kentaro, Matsumoto, Shigemi, Imamura, Chiyo K, Yamagiwa, Chiemi, Shimizu, Ayaka, Yoshino, Takayuki |
| author_sort | yamazaki, kentaro |
| container_start_page | 0 |
| container_title | Japanese Journal of Clinical Oncology |
| description | <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Adjuvant capecitabine and oxaliplatin (CAPOX) is a standard treatment for resected colon cancer; however, in patients with moderate renal impairment, the incidence of CAPOX-related adverse events (AEs) and the rate of early discontinuation are higher than in patients with no or mild renal impairment. The aim of this retrospective study was to assess the impact of baseline renal function on the safety and discontinuation of adjuvant CAPOX therapy started with the standard dose of capecitabine in elderly patients with colon cancer.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Data from patients aged ≥65 years old who received CAPOX at the standard starting dose as adjuvant therapy for stage II/III colon cancer were collected and analyzed retrospectively. Patients were divided into two groups based on their renal function: CLcr-H (patients with a creatinine clearance [CLcr] ≥50 ml/min) and CLcr-L (CLcr <50 ml/min), and AEs and discontinuations were assessed.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Overall, 189 patients were assessed (CLcr-H group = 137 and CLcr-L group = 52). No patients experienced grade 4 AEs. The incidence of grade 3 CAPOX-related AEs was higher in the CLcr-L group (42.3%) than in the CLcr-H group (31.3%). The proportion of patients who discontinued treatment within four cycles due to AEs was also higher in the CLcr-L group (21.1%) than in the CLcr-H group (2.9%). Multivariate analysis identified that CLcr <50 ml/min was the only significant risk factor for CAPOX therapy discontinuation due to AEs (P = 0.0008).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>This study demonstrates that the tolerability of adjuvant CAPOX therapy was decreased in elderly patients with impaired renal function.</jats:p> </jats:sec> <jats:sec> <jats:title>Clinical trial registration</jats:title> <jats:p>University Hospital Medical Information Network Clinical Trials Registry number UMIN000016446.</jats:p> </jats:sec> |
| doi_str_mv | 10.1093/jjco/hyz149 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9qamNvL2h5ejE0OQ |
| imprint | Oxford University Press (OUP), 2019 |
| imprint_str_mv | Oxford University Press (OUP), 2019 |
| institution | DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1 |
| issn | 1465-3621 |
| issn_str_mv | 1465-3621 |
| language | English |
| last_indexed | 2024-03-01T10:50:48.236Z |
| match_str | yamazaki2019clinicalimpactofbaselinerenalfunctiononsafetyandearlydiscontinuationofadjuvantcapecitabineplusoxaliplatininelderlypatientswithresectedcoloncanceramulticenterpostmarketingsurveillancestudy |
| mega_collection | Oxford University Press (OUP) (CrossRef) |
| physical | |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Oxford University Press (OUP) |
| record_format | ai |
| recordtype | ai |
| series | Japanese Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Yamazaki, Kentaro Matsumoto, Shigemi Imamura, Chiyo K Yamagiwa, Chiemi Shimizu, Ayaka Yoshino, Takayuki 1465-3621 Oxford University Press (OUP) Cancer Research Radiology, Nuclear Medicine and imaging Oncology General Medicine http://dx.doi.org/10.1093/jjco/hyz149 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Adjuvant capecitabine and oxaliplatin (CAPOX) is a standard treatment for resected colon cancer; however, in patients with moderate renal impairment, the incidence of CAPOX-related adverse events (AEs) and the rate of early discontinuation are higher than in patients with no or mild renal impairment. The aim of this retrospective study was to assess the impact of baseline renal function on the safety and discontinuation of adjuvant CAPOX therapy started with the standard dose of capecitabine in elderly patients with colon cancer.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Data from patients aged ≥65 years old who received CAPOX at the standard starting dose as adjuvant therapy for stage II/III colon cancer were collected and analyzed retrospectively. Patients were divided into two groups based on their renal function: CLcr-H (patients with a creatinine clearance [CLcr] ≥50 ml/min) and CLcr-L (CLcr <50 ml/min), and AEs and discontinuations were assessed.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Overall, 189 patients were assessed (CLcr-H group = 137 and CLcr-L group = 52). No patients experienced grade 4 AEs. The incidence of grade 3 CAPOX-related AEs was higher in the CLcr-L group (42.3%) than in the CLcr-H group (31.3%). The proportion of patients who discontinued treatment within four cycles due to AEs was also higher in the CLcr-L group (21.1%) than in the CLcr-H group (2.9%). Multivariate analysis identified that CLcr <50 ml/min was the only significant risk factor for CAPOX therapy discontinuation due to AEs (P = 0.0008).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>This study demonstrates that the tolerability of adjuvant CAPOX therapy was decreased in elderly patients with impaired renal function.</jats:p> </jats:sec> <jats:sec> <jats:title>Clinical trial registration</jats:title> <jats:p>University Hospital Medical Information Network Clinical Trials Registry number UMIN000016446.</jats:p> </jats:sec> Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study Japanese Journal of Clinical Oncology |
| spellingShingle | Yamazaki, Kentaro, Matsumoto, Shigemi, Imamura, Chiyo K, Yamagiwa, Chiemi, Shimizu, Ayaka, Yoshino, Takayuki, Japanese Journal of Clinical Oncology, Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study, Cancer Research, Radiology, Nuclear Medicine and imaging, Oncology, General Medicine |
| title | Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study |
| title_full | Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study |
| title_fullStr | Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study |
| title_full_unstemmed | Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study |
| title_short | Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study |
| title_sort | clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study |
| title_unstemmed | Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study |
| topic | Cancer Research, Radiology, Nuclear Medicine and imaging, Oncology, General Medicine |
| url | http://dx.doi.org/10.1093/jjco/hyz149 |